Tag:

Abbott

Latest Headlines

Latest Headlines

Abbott diagnostic enables faster, cheaper infection treatment

A new study suggests that a diagnostic from Abbott Laboratories offers a more accurate and faster diagnosis of the cause of blood-related infections. The in vitro diagnostic is expected to receive a CE mark in the coming months.

Abbott glucose monitor eliminates finger sticks, receives CE mark

Getting rid of the finger stick for diabetics while maintaining sufficient accuracy without calibration is a long-held industry goal and could prove a boon to patients.

VC Rock Health partners with Abbott, expands digital health portfolio

Venture Capital firm Rock Health announced today that it is adding 8 digital health companies to its portfolio and partnering with three industry bigwigs, including Abbott.

Abbott wins Medicare coverage, new tech add-on payments for MitraClip cardiology device

Abbott secured Medicare coverage for its MitraClip System to reduce the backward flow of blood through the heart's mitral valve (mitral regurgitation), the company announced Aug. 12. Earlier this month the federal Centers for Medicare and Medicaid services also approved the device for additional reimbursement in the form of new technology add-on payments due to its innovative nature. 

Leaders emerge in the race for the first U.S. bioresorbable stent

Most devices are launched in Europe before arriving in the U.S., and cardiology devices are certainly no exception to the rule.   Tough FDA premarket review standards, and the novelty of the technology, have turned the race to sell the first bioresorbable stent in the U.S. into a marathon. 

Registry data shows high risk of blood clot among users of Abbott's bioresorbable stent

Data from a European postmarket registry show that Abbott's Absorb BVS bioresorbable stent performs at a level similar to today's conventional drug-eluting stents on several measures, but not stent thrombosis. The risk of the stent being blocked by a blood clot was 3.4% after one year, a level of performance similar to prior generation drug-eluting stents, according to a recent EuroIntervention study.

Abbott med tech revenues up slightly as company prepares for sale of its generics unit

Abbott's medical device revenue was $1.37 billion in the second quarter, an increase of 1.2% year over year. Meanwhile, the diagnostics division reported quarter sales of $1.19 billion, a 4.8% increase, the company revealed July 16.

Abbott CEO: 'I don't feel the pressure to invert'

Wall Street analysts took advantage of a conference call on Abbott's just-announced sale of its developed market generics business to ask about some of their favorite topics, future M&A and the recent onset of  tax inversion mania among life science companies. 

Abbott continues evolution toward devices, planning to sell generics portfolio for $5.3B

Following the $5.3 billion sale of Abbott Laboratories' developed market generic drugs business to Mylan, diagnostics and devices will account for the majority of the company's sales, while pharmaceuticals' contribution to company-wide sales will stand at about 15%, based on 2013 earnings.  

Mylan beefs up outside the U.S. with $5.3B deal for Abbott drug business

Mylan has been hunting for a buy. Now, it's found one. The Pittsburgh-based generics specialist is buying a big chunk of Abbott Laboratories' drug business, in a stock swap worth $5.3 billion. With $2 billion in annual sales, the products would jack up Mylan's top line by almost 30%.